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Abstract 
Proteoglycans are mediators of cellular adhesion and regulate growth factor activities. Proteoglycans of B lymphocytes undergo 
structural changes during B cell ontogeny which may correspond to the specific requirements of the respective microenvironment of the 
maturing cell. We analyzed three human B cell lines representing pre-B cells (Nalm-6), activated B cells (Jok-l) and plasma cells (U266) 
for their cellular proteoglycans. Gel filtration of the 35S-labeled macromolecules of the three cell lines revealed an increase in size in the 
order Nalm-6 < Jok-1 < U266. In Jok-1 and U266 cells the major pool of proteoglycans consisted of proteochondroitin sulfates of 50 to 
90 kDa. These proteoglycans carried a protein core of approx. 30 kDa to which 1 to 3 glycosaminoglycan chains in the range of 28 to 32 
kDa were attached. In Nalm-6 cells only free chondroitin sulfate chains of 23 kDa, but no intact proteoglycans, were detected. 
Chondroitin sulfate chains were predominantly composed of chondroitin-4-sulfate, those of Nalm-6 and U266 cells additionally contained 
10-20% of unsulfated isaccharides. In U266 cells 30% of glycosaminoglycans consisted of heparan sulfate either bound to pure 
proteoheparan sulfate or to chondroitin sulfate/heparan sulfate hybrid-proteoglycans. Earlier, syndecan-1 was described as a hybrid 
proteoglycan containing heparan sulfate/chondroitin sulfate chains which is transcribed by murine B cells at early and late maturation 
stages. In order to see whether syndecan is transcribed by the human B cell lines used here, we measured expression of syndecan mRNA 
by the reverse transcriptase polymerase chain reaction. Similar to murine lymphocytes, syndecan-specific mRNA was detected in Nalm-6 
and U266 cells, equivalent to early and late B cells, but not in lymphoblastoid Jok-1 cells, However, Nalm-6 cells do not produce 
proteoheparan sulfate. In these cells, syndecan synthesis may be blocked at the translational level. Also, the proteoglycans of U266 are 
different from syndecan-1 in their composition of glycosaminoglycans d in size of protein cores. Together, these results indicate that 
the major pool of proteoglycans produced by human B cells consists of proteochondroitin sulfate and additionally in later stages of a 
smaller proportion of proteoheparan sulfate which is not identical to syndecan-1. During distinct phases of B cell differentiation, 
modulations in the glycosaminoglycan moiety concerning size and sulfation of glycosaminoglycan chains were also found. 
Keywords: Proteoglycan; Glycosaminoglycan; Sulfation; B cell differentiation; Syndecan 
1. Introduction 
B lymphocytes adhere to other cells and to extracellular 
matrix and respond to a variety of growth factors during 
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their maturation. Different microenvironments require a 
precisely regulated expression of cell surface receptors 
mediating adhesion and responses to growth factors [1,2]. 
Proteoglycans have been described as cell-to-matrix adhe- 
sion molecules and modulators of growth factor activities 
[3-5]. These functions make them potentially important 
regulatory molecules for lymphocyte maturation. Lympho- 
cytes predominantly synthesize proteoglycans with chon- 
droitin sulfate (CS) chains [6,7], but in some cell types, as 
for instance thymocytes, heparan sulfate (HS) was also 
found [8,9]. 
Several proteoglycans, defined by their protein struc- 
tures, have been described to be expressed by B cells. Two 
glycoproteins, the homing receptor CD44 and the invariant 
chain associated to the major histocompatibility complex 
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(MHC) class II, are in s:mall quantities also expressed as 
proteochondroitin sulfate,; (CSPG) [10,11]. These two pro- 
teoglycans certainly do not represent the major pool of 
proteoglycans produced by human B lymphocytes. The 
proteoheparan sulfate (HSPG) syndecan-1 is expressed on 
murine pre-B and plasma cells, while it is absent on 
mature circulating lymphocytes [12]. Syndecan has earlier 
been described to bind tc, collagen type I, III, and V [13], 
fibronectin [14] and thrombospondin [15]. In a more recent 
study syndecan transcription was detected by the reverse 
transcriptase-polymerase chain reaction on human myeloma 
cell lines and its expressi,an shown by immunodot blotting 
[16]. It was postulated that syndecan is involved in adhe- 
sion of myeloma cells to bone marrow stromal cell matrix. 
In a previous tudy we provided evidence that human B 
cells produce proteoglycans in large quantities which are 
different in their protein moieties from the invariant chain, 
CD44 and syndecan [17]. These proteoglycans, isolated 
from the human lympho~lastoid B cell line LICR-LON- 
HMy2, consisted of CSPG with a molecular mass of 
approximately 135 kDa. 
The carbohydrate moiety of proteoglycans renders many 
functional properties [3] and may influence differentiation 
and activation of hematopoetic cells [18-20]. Provided that 
proteoglycans are functio:aally involved in B cell differen- 
tiation, one would expect qualitative and quantiative alter- 
ations in these B cell-expressed proteoglycans according to 
the specific requirement:~ of distinct maturation stages. 
Therefore, a detailed structural analysis of proteoglycans 
derived from human B lymphocytes of various maturation 
stages is a prerequisite to gain insights into the fine 
regulation of proteoglycan-mediated processes. 
Following this hypothesis we investigated three human 
B cell lines for their proEeoglycan production. These cell 
lines represent different maturation stages, ranging from 
the pre-B cell (Nalm-6), Io mature B cells (Jok-1) and the 
plasma cell stage (U266). We found that during B cell 
differentiation proteoglycans are modified in their glyco- 
saminoglycan (GAG) mo!iety. Changes in CS chains were 
observed in terms of chain sizes and sulfation patterns. The 
CSPG isolated from Jok-1 and U266 cells have similarities 
to those proteoglycans produced by the human B cell line 
LICR-LON-HMy2 [17]. In myeloma cells a significant 
portion of HSPG was present. These HSPGs have several 
characteristics which distinguish them from syndecan-1 
[21]. 
Changes in the GAG moiety of proteoglycans may 
affect heir functions. For instance, a shift from HS to CS 
chains has been reported for proteoglycans of tumor cells 
after SV-40 transformation which may be associated with 
the acquisition of a malignant phenotype [22]. Also, the 
fine structure of HS chains linked to the syndecan-I 
protein core may regulate its properties as cell-matrix 
adhesion molecules [23]. 
In a similar fashion changes in proteoglycan glycosyla- 
tion reported in this study suggest differential functions of 
proteoglycans during B cell development in which glyco- 
sylation may contribute to receptor properties of proteogly- 
cans. 
2. Materials and methods 
2.1. Materials 
H ~5 SO 4 was  purchased from DuPont-New England Nu- 
clear (Boston, MA, USA), Na125I from Amersham Buchler 
(Braunschweig, Germany); prepacked PD10-columns, 
DEAE-Sephacel, Sepharose CL-4B and Superose 6 (HR 
10/30) from Pharmacia LKB Biotechnology (Freiburg, 
Germany), BioGel P10, BioRad assay for protein determi- 
nation and a BioSil Amino5S-column from Bio-Rad 
(Munich, Germany); ultrapure guanidinium chloride and 
urea, NEM, PMSF, CHAPS and Iodobeads were from 
Sigma (Munich, Germany), and the ultrafiltration equip- 
ment from Millipore (Eschborn, Germany). The disaccha- 
ride standards as well as the enzymes chondroitinase ABC 
(EC 4.2.2.4) and heparitinase (EC 4.2.2.8) were purchased 
from Seikagaku Kogyo (Tokyo, Japan), chondroitinase AC 
(EC 4.2.2.5) from Sigma. The culture medium RPMI 1640 
and fetal calf serum were purchased from Gibco (Eggen- 
stein, Germany). GAG standards (CS/dermatan sulfate 45 
kDa, keratan sulfate 25 kDa, keratan sulfate 18 kDa) were 
kindly provided by Dr. H.W. Stuhlsatz, University of 
Aachen, Germany. RNAsin and moloney murine leukemia 
virus reverse transcriptase were from Promega, Heidel- 
berg, Germany, and Taq DNA polymerase from Strata- 
gene, La Jolla, CA. 
2.2. Cell culture and labeling 
The human B cell lines Nalm-6, patient-derived from an 
acute lymphocytic leukemia [24], Jok-1, from a hairy cell 
leukemia [25] and U266, a myeloma line [26], were grown 
in suspension culture using RPMI 1640 containing 10 mM 
Hepes, 5% heat inactivated fetal calf serum and 2 mM 
L-glutamine. For radioactive labeling of proteoglycans, 
0.37 MBq/ml H~5SO4 were  added to 1 • 10 6 cells/ml in 
sulfate free RPMI for 24 h. These labeling conditions 
resulted in maximum incorporation of 35SO4 into proteo- 
glycans. As determined in previous experiments, the use of 
sulfate-free medium for labeling apparently did not result 
in altered glycosylation and sulfation of proteoglycans in 
comparison to labeling in regular RPM! 1640 medium. 
Moreover, unlabeled proteoglycans extracted from cells 
cultivated in regular RPMI 1640 and determined by a 
spectrophotometric microassay [27] had identical elution 
profiles in CsC1 density-gradient ultracentrifugation a d 
ion-exchange chromatography to 35S-labeled proteoglycans 
received from cells cultured in sulfate-free medium. 
Cultures were centrifuged at 400 × g for 10 rain and 
cell pellets were collected. To measure the incorporation of
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SsS-label into macromolecules, cells were washed twice 
with phosphate-buffered saline and subsequently sed in 
buffer A (4 M guanidine-HCl, 0.1 M Tris, 1 mM EDTA, 1 
mM NEM, l mM PMSF (pH 7.5)) containing additionally 
1% CHAPS (w/v)  and aprotinin (1 /xg/ml), at 4°C 
overnight. After centrifugation for 15 rain at 17000 X g 
the cellular extracts were desalted on a prepacked PD10 
column and eluted with buffer A containing 0.1% CHAPS 
(w/v)  and aprotinin (! /zg/ml). An aliquot of pooled 
macromolecules in the void volumes of the PD 10 column 
was used to calculate the amount of incorporated radioac- 
tivity. 
2.3. Isolation of proteoglycans 
In order to isolate cellular proteoglycans, labeled and 
unlabeled cells were combined in a ratio of 1:10 and lysed 
in buffer A containing 1% CHAPS (w/v)  and aprotinin (1 
/xg/ml). After shaking at 4 ° C overnight, the lysate was 
sonicated three times each for 10 s and centrifuged at 
4000 × g for 20 min. Subsequently, the supernatant was 
used for CsCI density-gradient ultracentrifugation. The 
cellular extracts were lysed in buffer A and brought o a 
starting density of 1.45 g /ml  by adding solid CsCI. After 
centrifugation at 200000 X g at 20°C for 18 h (40 ml 
quickseal tubes, Beckman L2-centrifuge, VTI 50-rotor), 
fractions of 2 ml were collected from the bottom of the 
tube and analyzed for their density and [35S]sulfate-incor- 
poration. Protein content was determined using the Bio-Rad 
assay. Fractions 1 and 2 with the highest density and the 
highest content of SsS-labeled material were collected as 
preparation A and used for the purification of proteogly- 
cans. In some experiments fractions 3 to 6 were pooled as 
preparation B and analyzed similarly. 
Macromolecular material was precipitated with 80% 
ethanol (v /v)  and subsequently applied to anion-exchange 
chromatography. A column of DEAE-Sephacel (1 x 5 cm) 
was equilibrated with 7 M urea, 0.1 M Tris, 1 mM 
EDTA/NEM/PMSF,  0.1% CHAPS (w/v)  (pH 7.5). Col- 
umn-bound proteoglycans and GAGs were eluted with a 
40 ml gradient of 0 to 1 M NaCI in the same buffer. 
Fractions of 0.75 ml were collected. The 3SS-containing 
peak fractions were pooled and macromolecules precipi- 
tated with 80% ethanol. 
The precipitate was resuspended in buffer A and then 
subjected to a column of Sepharose CL-4B (1 X 95 cm, 
flow rate 4 ml/h)  equilibrated in the same buffer. Frac- 
tions of 1 ml were collected and measured for their content 
of 35S-labeled material. The appropriate fractions were 
pooled and brought o a concentration of 80% ethanol. 
2.4. Enzymatic digestions and B-elimination 
Samples of 3s S-labeled material (5000-10 00 cpm each, 
purified as described above), were digested with 0.15 units 
of chondroitinase ABC and AC, respectively, in a total 
volume of 20 to 50 p~l 0.1 M Tris, 0.1 M NaC1 (pH 7.5) at 
37 ° C for 15 h, or with 2.5 units of heparitinase in 0.1 M 
Tris, 0.1 M NaCI, 10 mM CaC12 (pH 7.5) at 37°C for 15 
h. The incubation mixtures were then boiled for 3 min to 
terminate nzymatic degradation. No proteolytic activity 
was found in the enzymatic preparations used as tested by 
incubation of bovine serum albumin with GAG degrading 
enzymes for 24 h and subsequent protein separation on 
SDS-polyacrylamide g l electrophoresis. 
For alkaline /3-elimination, portions of purified proteo- 
glycans were treated with 0.5 M NaOH containing 1 M 
NaBH 4 at room temperature for 16 h. The reaction was 
terminated by adding 33% acetic acid (v /v)  while cooling 
with ice. The molecular mass of the GAG chains was 
analyzed by separation on a Superose 6 column calibrated 
with GAG standards. 
In order to analyze the GAG composition of proteogly- 
cans, the 35S-labeled molecules were treated with chon- 
droitinase ABC or heparitinase and the reaction products 
analyzed on a Superose 6 column (1 X 28 cm, flow rate 
0.3 ml/min) eluted with 0.1 M Tris-HCl, 1 mM EDTA, 
0.1% SDS (w/v)  (pH 7.5) using a FPLC-chromatography 
system from Pharmacia. Fractions of 0.5 ml were col- 
lected. 
2.5. Analysis of the disaccharide composition 
After treatment of purified proteoglycans and GAGs 
with chondroitinase ABC or AC, samples were boiled for 
5 min and after cooling down to 4 ° C, mixed with a 4-fold 
excess of ethanol in order to precipitate proteins overnight. 
After centrifugation for 15 min at 17 000 x g, the super- 
natants containing the disaccharides were collected and 
dried in a SpeedVac (Bachofer, Reutlingen). The pellet 
was redissolved in water and analyzed on a BioSil Amino5S 
HPLC column eluted with 150 mM NaH2PO 4, pH 4 (flow 
rate of 1 ml/min), using the Beckmann HPLC 'Gold'-sys- 
tem (Munich, Germany). Disaccharides were detected at 
232 nm and retention times were compared to those of 
standards of CS disaccharides. 
2.6. Characterization of core proteins 
Purified proteoglycans (approximately 20 /~g) were ra- 
dioiodinated with 18.5 MBq Na125I using bead-coupled 
chloramine T (Iodobeads). For separation from free 12si 
the reaction products were desalted on prepacked PDI0- 
columns. To determine the molecular mass of the core 
proteins, samples were digested with chondroitinase ABC 
and heparitinase (incubation time 3 h at 37 ° C) and sepa- 
rated on SDS-polyacrylamide g ls under reducing condi- 
tions according to the method of Laemmli [28]. 
2.7. RNA-isolation and reverse-transcriptase polymerase 
chain reaction 
For the isolation of total cellular RNA 1 • 108 cells were 
washed twice with phosphate-buffered saline, lysed in 10 
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mM Tris (pH 7.6) containing 15 mM NaC1, 2 mM MgC12 
and 0.5% NP-40. After incubation for 5 min on ice the 
lysate was centrifuged for 5 min at 13 000 rpm in an 
Heraeus Biofuge 13. The supernatant was added to 10 mM 
Tris (pH 7.6) containing 150 mM NaC1, 5 mM EDTA in a 
ratio of 1:1 (v /v)  and e, xtracted with phenol (pH 4.5). 
After incubation for 5 rain at 55°C the solution was 
centrifuged for 5 min at 13 000 rpm as described above, 
and the supernatant was subjected to a second phenol-ex- 
traction. 
Following centrifugation, chloroform/isoamylalcohol 
(24:1, v /v )  was added to the supernatant, and after further 
centrifugation the upper phase containing the RNA was 
mixed with sodium acetate (final concentration 0.1 M) and 
then precipitated with 2.5 volumes of ethanol. The final 
pellet was dissolved in TE (10 mM Tris (pH 7.4), 0.1 mM 
EDTA) with RNAsin (20 units), and the concentration of 
RNA was determined photometrically at260 rim. 
For cDNA synthesis, 6.5 /zg of total RNA were incu- 
bated with oligo (dT) 15 primer and 800 units of Moloney 
murine leukemia virus reverse transcriptase for 1 h at 
37 ° C. The reverse transcriptase was inactivated at 95°C 
for 10 min. 
The polymerase chain reaction was performed on this 
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DEAE-Sephacel were applied to a Sepharose CL-4B gel filtration column. Fractions of 1 ml were collected and 35S-radioactivity of 30 /zl aliquots was 
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cDNA using 150 ng of cDNA, 30 nmol of each primer and 
2.5 units of Taq DNA polymerase. Cycle conditions were 
as follows: 35 cycles with 1 min at 95 ° C, 2 min at 60 ° C, 
followed by 3 min at 72 ° C. Primers for syndecan- 1 specific 
amplification were derived from published sequences [29] 
as follows: the forward primer (5'-AGCCAAGCTFACCT- 
TCACAC-3') with position 716-736, the reverse primer 
(5'-TAGAATTCCTCCTGTrTGGTGG-3') with position 
1132-1110. The expected fragment size is 416 bp. Aliquots 
of 10 /zl of the amplification product were analyzed by 
electrophoresis on a 1.5% agarose gel containing 0.5 /zg 
/ml  ethidium bromide. 
3. Results and discussion 
3.1. Purification of proteoglycans 
Cells of the human B cell lines Nalm-6, Jok-1, and 
U266 were metabolically abeled with [ 35 S]sulfate for 24h. 
After 35S-labeling, proteoglycans were isolated from cellu- 
lar extracts of the three cell lines by sequential steps of 
CsCI density-gradient centrifugation, anion-exchange chro- 
matography and gel filtration. 
Cellular extracts were subjected to CsCI density-gradi- 
ent ultracentrifugation under dissociative conditions. After 
centrifugation, most of the 35S-label was found in the 
fractions of highest density, while the major portion of 
proteins was determined in lower-density fractions (Fig. 
1A). The combined fractions 1 and 2 from the bottom of 
the tube (indicated in Fig. 1A as preparation A) were used 
for the purification of high density proteoglycans. The 
consecutive fractions 3 to 6 (preparation B) were also 
pooled and chromatographically separated. For each cell 
type the elution profiles of preparations A and B were 
identical in anion exchange and gel filtration chromatog- 
raphy (profiles not shown). Further analysis of the glyco- 
saminoglycan and the protein moieties of proteoglycans 
was done with the material of high density fractions, since 
it contained the highest content of proteoglycans. 
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Sulfated macromolecules of cell lines Jok-1 and U266 
enriched from the first preparation step eluted on a 
DEAE-Sephacel column as broad peak in the range of 
0.3-0.5 M NaCI, those of Nalm-6 cells between 0.4 and 
0.6 M NaC1. 
After anion-exchange chromatography the fractions 
containing the 35S-labeled glycoconjugates were pooled, 
precipitated and further chromatographed on Sepharose 
CL-4B (Fig. 1B). 
Gel filtration of the 35S-labeled macromolecules of the 
three cell lines revealed ;m increase in size in the order 
Nalm-6 < Jok-I < U266. The preparation of U266 eluted 
as a broad peak with Kay := 0.48 (Fig. 1B). Compared with 
the sizes of GAG standards, the sizes of proteoglycans 
from Jok- 1 and U266 were in the range of 50 to 90 kDa. In 
Nalm-6 no intact proteoglycan could be detected as out- 
lined below. 
3.2. Size determination fGAG chains 
In order to investigate I:he presence of intact proteogly- 
cans and to determine the sizes of GAG chains of proteo- 
glycans, 35S-labeled material of cellular preparations was 
chromatographed on Superose 6 with and without prior 
alkaline fl-elimination (Fig. 2A). The elution profiles of 
the untreated preparations were comparable to those ob- 
tained by chromatography on Sepharose CL-4B. 
NaOH/NaBH4-treatment showed no obvious shift in 
molecular mass with sulf;tted macromolecules of Nalm-6 
cells (Fig. 2A). Therefore, it seems likely that the 35S- 
labeled material extracted from Nalm-6 cells predomi- 
nantly contains free GAG chains. However, we cannot 
completely rule out the possibility that proteoglycans with 
single GAG chains occur, beating in mind that the migra- 
tion behaviour of proteoglycans in gel filtration chro- 
matography largely depends on the size of the carbo- 
hydrate components, provided the protein core is compara- 
tively small. On the other hand, as outlined below, we 
could not demonstrate he presence of a protein core of 
sulfated glycoconjugates derived from Nalm-6 cells as we 
could do with the proteoglycan preparations of the two 
other cell lines. Therefore, the predominant presence of 
free GAG chains is more likely in Nalm-6 cells. The 
occurrence of a pool of free GAG in the cellular compart- 
ment has previously been described by us and others for B 
cells [17], T cells [30], monocytes [7,31], HL-60 cells [32] 
and a multipotent s em cell line [6]. This intracellular pool 
of free GAG chains may result from rapid degradation of 
intact proteoglycans as demonstrated for the B cell line 
LICR-LON-HMy2 [17]. 
Alkaline treatment of 35S-labeled molecules of Jok-1 
resulted in a slight shift of the main peak (Fig. 2A). A 
small peak at fraction 15 eluting before the main peak of 
Jok-1 disappeared completely after alkaline treatment. The 
size of U266-derived material was reduced to a higher 
extent by this treatment. Since the elution profiles of 
untreated and alkaline-treated sulfated cellular molecules 
from Jok-1 and U266 cells overlapped to a considerable 
extent, preparations of 35S-labeled macromolecules seemed 
to contain a portion of free GAG chains in addition to 
intact proteoglycans. 
The size of the GAG chains after alkaline/3-elimination 
was estimated on Superose 6 using GAGs of defined 
molecular mass standards. The proteoglycans from Nalm-6 
had GAG chains with the smallest size (on average 23 
kDa), followed by those of Jok-1 (28 kDa) and of U266 
with the highest molecular mass (32 kDa). 
3.3. Nature of the GAG chains 
Aliquots of preparations obtained after CsC1 density- 
gradient centrifugation were chromatographed on Superose 
6 with and without prior digestion by chondroitinase ABC 
or heparitinase (Fig. 2B). The percentage of CS and HS 
contained in the respective preparation was estimated by 
determining the amount of radioactivity found in the total 
volume (V t) after specific enzymatic treatment in relation 
to the radioactive label of untreated peak material (Table 
1). 
Because lution profiles after chondroitinase ABC and 
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Table 1 
Chondroitin sulfate and heparan sulfate composition of cellular proteogly- 
cans 
Cell line Composition (% of total 35 S-labeled macromolecules) 
CS HS 
Nalm 6 99 +__ 3 < 1 
Jok-1 98_+3 ~ 1 
U266 67 _+ 10 33 _+ 10 
Proteoglycans and GAGs isolated from cellular extracts were subjected to 
chondroitinase ABC and heparitinase digestion and subsequently applied 
to a Superose 6 column as indicated in Section 2. The amount of 
disaccharides and oligosaccharides, which eluted after enzymatic treat- 
ment in the V t of the column, was estimated by measurement of 35S-label 
in the V t and used to calculate the percentage of CS and HS in the 
respective preparation. Values are presented as mean+S.D, of three 
independent experiments. 
AC treatment were identical (data for chondroitinase AC 
not shown), no dermatan sulfate seemed to be present in 
these three B cell lines. In preparations of Nalm-6 and 
Jok-1 only CS was observed. In contrast, the myeloma cell 
line U266 showed a considerably high content of HS 
(Table 1). 
The molecular mass of proteoglycans from U266 cells 
was reduced after treatment both with heparitinase and 
chondroitinase (Fig. 2B, arrows I and II), but still remained 
slightly larger in size than the average of the single GAG 
chains obtained after/3-elimination (Fig. 2A). This points 
to the possibility that at least a part of the proteoglycans 
may exist as hybrid proteoglycans with CS and HS chains 
attached to one protein core. 
Further, 35S-labeled material of U266 cells eluted as 
one peak and after alkaline treatment as two peaks in 
anion-exchange chromatography (Fig. 3). Apparently, in 
proteoglycans from U266 cells two differently charged 
GAG entities are linked to the same protein core. This 
observation adds further proof to the existence of hybrid 
proteoglycans in U266 cells. 
The disaccharide composition of the CS chains of pro- 
teoglycans was analyzed by HPLC (Table 2). It could be 
shown that Di-4S was the main disaccharide component of 
proteoglycans in all three cell lines. Di-6S was also de- 
tected in trace amounts in preparations of U266 and Nalm-6 
cells. 
Table 2 
Composition of chondroitin sulfate disaccharides 
Cell line Composition (% of total CS) 
ADi-0S ADi-4S ADi-6S 
Nalm 6 18+2 (4) 80___3 (4) 2+0.8 (4) 
JOK-1 4+ 3 (3) 96-1-4 (3) < 1 (3) 
U266 15 _+7 (3) 84_+ 15 ~ 1 (3) 
Proteoglycans and free GAG chains derived from cellular extracts were 
subjected to chondroitinase ABC digestion. The resulting unsaturated 
disaccharides (ADi-0S, ADi-4S and ADi-6S) were identified by HPLC 
on a BioSil Amino5S-column. Values are shown as mean + S.D. of 3 to 4 
experiments (number of experiments are given in parentheses). 
Jok-1 I U266 
-69  
i 1 i i 
1 2 3 1 2 3 
Fig. 4. Autoradiograms of radioiodinated proteoglycans and core proteins 
from lysates of Jok-I and U266 cells. Proteoglycans without treatment 
(lane 1) and treated with heparitinase (lane 2) or with chondroitinase 
ABC (lane 3) were separated on SDS-gel electrophoresis. Undigested 
preparations of cellular proteoglycans may contain trace amounts of 
glycosaminopeptides migrating in the range of 40 to 30 kDa. Protein 
cores with undigested CS and HS residues after respective nzymatic 
treatment did not enter the 15% polyacrylamide gel. Migration of stan- 
dard proteins is indicated at the right margin. 
Di-0S was found in all three cell lines, in Nalm-6 and 
U266 to a higher degree than in Jok-1. Differences in the 
content of Di-0S influence the negative charge of the 
corresponding proteoglycans. 
3.4. Characterization of core proteins 
Radioiodination of purified proteoglycans by the 
iodobead technique and subsequent chondroitinase ABC 
digestion of proteoglycans from Jok-1 and U266 generated 
a protein band of 30 kDa (Fig. 4). This observation 
supports the finding that a large portion of proteoglycans 
in cellular preparations exclusively contained CS as GAG. 
Treatment of the samples with heparitinase r sulted in the 
appearance of a weaker protein band of 32 kDa in prepara- 
tions of U266 cells (Fig. 4). Therefore, additionally in 
U266 cells, a minor portion of pure HSPG seems to be 
present. Cellular preparations of Nalm-6 could not be 
labeled with 1251, which further indicates that these prepa- 
rations did not contain measurable amounts of intact pro- 
teoglycans as shown in Fig. 2A. Since in kinetic degrada- 
tion experiments with incubation periods ranging from 1 to 
15 h no protein band different o the 30 kDa band became 
visible (data not shown), and secondly no proteolytic 
activity was detectable in the enzyme preparations, we 
reason that the 30 kDa protein core is not a proteolytic 
split product. 
In summary, our results indicate that the main portion 
of cellular proteoglycans of Jok-1 and U266 cells are of 
CSPG. A smaller portion of U266 proteoglycans may 
consist of hybrid proteoglycans containing HS and CS as 
indicated by elution profiles of ion exchange and gel 
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filtration chromatography. A further portion of U266 pro- 
teoglycans may represent pure HSPG. 
The sizes of the GAGs (23 to 32 kDa) and the size 
estimations of intact proteoglycans (50 to 90 kDa, Figs. 1, 
2) are consistent with an average of 1 to 3 GAG chains per 
proteoglycan. Therefore, assuming 2 to 3 GAG chains 
attached to a protein core of approximately 30 kDa, cellu- 
lar high density proteoglycans of human B cells have a 
molecular mass of 100 to 120 kDa. 
Synthesis of these proteoglycans in the B cell lines 
investigated seems to be stable, since repetitive analyses 
over a period of 3 years did not reveal significant alter- 
ations of their structures. This corroborates the assumption 
that proteoglycan synthesis of B lymphocytes i  regulated 
in a way typical for the respective maturation stage. 
Similar size estimations have been made for proteogly- 
cans of other hematopoietic cells: human peripheral blood 
mononuclear cells secrete a CSPG of 130 kDa, with four 
CS chains of 25 kDa each, attached to a protein core of 35 
kDa [33]; human platelet CSPG (136 kDa) contains four 
CS chains of each 28 kDa linked to protein core of 27 kDa 
[34]. The sizes of proteoglycans secreted by human T cells 
are in the same range [301r. 
3.5. Expression of the syndecan gene 
Since the HSPG syndecan has been described to be 
expressed on murine B cells of early and late maturation 
phases [12] and on human myeloma cells [16], we investi- 
gated syndecan transcripti,3n on the B cell lines used here. 
A syndecan-specific transcript of 416 bp was detected in 
cell lines Nalm-6 and U2,56 (Fig. 5). Cell line Jok-1 was 
deficient in syndecan tran:~cription. As positive control we 
used the human mammary epithelium cell line HBL-100 
described for syndecan production [35]. Syndecan is a 
HSPG which may in some cells also contain a small 
. 
416 bp 
Fig. 5. PCR amplification of syndecan-1 sequences from B cell lines and 
the mammary epithelial cell line HBL-100. Total RNA was subjected to 
reverse transcriptase and polymerase chain reaction amplification using 
syndecan-1-specific primers as d,escribed in Section 2. Amplification of 
contaminating genomic DNA in total RNA preparations was excluded by 
using primers which are derived from sequences of different exons. As 
positive control we used cell line HBL-10 which was described to express 
syndecan- 1 [35]. 
amount of CS bound to the same protein core [36]. Using 
syndecan-specific amplification primers, synthesis of 
mRNA for syndecan was also demonstrated in U266 cells 
by another group [16]. How does the presence of synde- 
can-specific mRNA in Nalm-6 and U266 cells correlate to 
the biochemical analysis of proteoglycan structures of this 
study? Since in the pre-B cell line Nalm-6 we did not find 
HSPG and further, syndecan has not been described as a 
pure CSPG; neither is it present in these cells nor does it 
exist in amounts measurable by biochemical methods ap- 
plied here. It is most likely that syndecan expression in 
Nalm-6 cells is post-transcriptionally downregulated. It has 
already been described for several cell systems that synde- 
can mRNA is accumulated in cells and is only translated 
upon external stimuli. For example in murine peritoneal 
macrophages, yndecan-1 expression can be induced by 
cAMP [37]. For murine pre-B cells syndecan-1 expression 
has been shown by immunostaining [12]. It may well be 
that in human pre-B cells syndecan-1 expression is regu- 
lated differently. 
In U266 cells, HS is a constituent of hybrid proteogly- 
cans and of pure HSPG. However, HSPG of U266 cells 
does not resemble syndecan as it has been described for 
murine B cells [21]. In contrast to the murine myeloma cell 
line MPC-11, hybrid proteoglycans of U266 cells contain 
CS chains in larger proportions. For syndecan of MPC-11 
cells [21] and mesenteric lymph node cells, a protein core 
of 62 kDa and for syndecan of murine bone marrow B 
cells a protein core of 76 kDa was observed in SDS-poly- 
acrylamide gels [12]. These results are in contrast o the 
protein core of 30/32 kDa we found for all proteoglycans 
isolated from human B cells. Given that we have identified 
syndecan-specific mRNA in U266 cells, it may be that 
these cells express syndecan in a form different o that 
reported for other cells or in very low amounts which 
could not be detected by the biochemical analysis applied 
here. 
Our results demonstrate that U266 cells produce a 
heterogeneous population of proteoglycans in terms of 
glycosylation. Certainly, U266 cells additionally produce 
other proteoglycans than syndecan. The relation of the 
hybrid proteoglycan of U266 cells to other known proteo- 
glycans has to be clarified. 
In Jok-1 cells syndecan is not transcribed as shown by 
the reverse transcriptase-polymerase chain reaction. These 
cells synthesize primarily CSPG. The CSPG isolated from 
Jok-1 and U266 cells resembles those previously described 
for platelets [34], monocytic ells [38], NK and T cells 
[30]. Further, the cellular CSPG of Jok-1 is similar to the 
CSPG found in the B cell line LICR-LON-HMy2 which 
carries a protein core not identical to proteoglycans of the 
serglycin or syndecan families [17]. Therefore, we presume 
that hematopoietic cells may contain a major proteoglycan 
which is not identical to those proteoglycans defined by 
their protein sequence as, for instance, syndecans and 
serglycins. 
14 s. Engelmann et al. / Biochimica et Biophysica Acta 1267 (1995) 6-14 
The expression of HS/  CS hybrid proteoglycans and 
HSPG at late stages of human B cell development may 
have functional consequences, ince binding properties of 
HS and CS to extracellular matrix components or growth 
factors are different [5]. The study of the interactions 
between B cell-derived proteoglycans and such molecules 
will give new perceptions in the general functions of B cell 
proteoglycans. 
4. Conclusions 
Taken together, the results presented here demonstrate 
that B cells undergo changes in synthesis of GAG chains 
and proteoglycans during their differentiation. Sizes of 
GAG chains increase from Nalm-6 to Jok-1 and U266 
cells. No intact protoglycans could be isolated from Nalm-6 
cells. These cells contained free CS chains. In Jok-1 cells a 
homogeneous population of CSPG was found and finally 
in U266 cells at least three different species of proteogly- 
cans were present: a CSPG, a hybrid proteoglycan with 
CS/HS chains, and an HSPG. Further we found that sizes 
of GAG chains gradually increased from the stage of pre-B 
cells to that of activated B cells and plasma cells. Also, 
sulfation patterns of CS chains were modulated. CS chains 
of Nalm-6 and U266 cells contained a higher proportion of 
unsulfated chondroitin than those of Jok-1 cells. 
Changes found in the glycosylation of B cell proteogly- 
cans may be closely related to the proposed different 
functions of proteoglycans during B cell maturation. 
Syndecan described to be expressed by U266 cells [16] 
does not seem to be identical to the major species of 
proteoglycans characterized here because of its different 
structural characteristics. 
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